SG11202103183PA - Agents and methods for modulating pathogen activity - Google Patents
Agents and methods for modulating pathogen activityInfo
- Publication number
- SG11202103183PA SG11202103183PA SG11202103183PA SG11202103183PA SG11202103183PA SG 11202103183P A SG11202103183P A SG 11202103183PA SG 11202103183P A SG11202103183P A SG 11202103183PA SG 11202103183P A SG11202103183P A SG 11202103183PA SG 11202103183P A SG11202103183P A SG 11202103183PA
- Authority
- SG
- Singapore
- Prior art keywords
- agents
- methods
- pathogen activity
- modulating
- modulating pathogen
- Prior art date
Links
- 230000000694 effects Effects 0.000 title 1
- 244000052769 pathogen Species 0.000 title 1
- 230000001717 pathogenic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739025P | 2018-09-28 | 2018-09-28 | |
| PCT/AU2019/051055 WO2020061649A1 (en) | 2018-09-28 | 2019-09-30 | Agents and methods for modulating pathogen activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103183PA true SG11202103183PA (en) | 2021-04-29 |
Family
ID=69949189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103183PA SG11202103183PA (en) | 2018-09-28 | 2019-09-30 | Agents and methods for modulating pathogen activity |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210338685A1 (es) |
| EP (2) | EP3856196B1 (es) |
| KR (1) | KR20210069086A (es) |
| CN (1) | CN113164494A (es) |
| AU (1) | AU2019348194A1 (es) |
| BR (1) | BR112021005955A2 (es) |
| CA (2) | CA3224977A1 (es) |
| DK (1) | DK3856196T3 (es) |
| MX (1) | MX2021003730A (es) |
| SG (1) | SG11202103183PA (es) |
| WO (1) | WO2020061649A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111184707B (zh) * | 2020-02-20 | 2021-04-27 | 中山大学 | 托芬那酸或其药学上可接受的盐在制备预防和/或治疗新型冠状病毒炎症药物中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2948718A (en) | 1960-08-09 | New n-heterocyclic compounds | ||
| US2554736A (en) | 1951-05-29 | Tertiary aminoalkyl-iminodibenzyls | ||
| US2868818A (en) | 1953-12-15 | 1959-01-13 | Merck & Co Inc | Alpha methyl phenylalanines |
| US3515785A (en) | 1958-12-06 | 1970-06-02 | Geigy Chem Corp | Compositions and methods for treating endogenous depression with 3-chloro - 5 - (gamma - dimethylamino - propyl)-iminodibenzyl |
| DE1142870B (de) | 1959-11-16 | 1963-01-31 | Geigy Ag J R | Verfahren zur Herstellung von Azepinderivaten |
| US3138636A (en) | 1960-06-23 | 1964-06-23 | Parke Davis & Co | Anthranilic acid derivatives |
| US3462536A (en) | 1960-07-22 | 1969-08-19 | Merck & Co Inc | Method of inhibiting decarboxylase |
| US3454554A (en) | 1960-10-14 | 1969-07-08 | Colgate Palmolive Co | Aminoalkyliminodibenzyl compounds |
| US3313848A (en) | 1964-06-18 | 1967-04-11 | Parke Davis & Co | Anthranilic acids and derivatives |
| FR1532301A (fr) | 1967-01-18 | 1968-07-12 | Rhone Poulenc Sa | Nouveaux dérivés de la dibenzazépine et leur préparation |
| CH500196A (de) | 1969-03-10 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Azepinderivaten |
| US4092430A (en) | 1970-09-09 | 1978-05-30 | Ciba-Geigy Corporation | Antiphlogistic phenylacetohydroxamic acid compositions |
| US4692441A (en) * | 1985-08-16 | 1987-09-08 | Merck & Co., Inc. | Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities |
| DE3811119C1 (es) | 1988-03-31 | 1989-10-12 | Merckle Gmbh, 7902 Blaubeuren, De | |
| IT1226902B (it) | 1988-07-12 | 1991-02-21 | Mini Ricerca Scient Tecnolog | Processo per la sintesi del levodopa |
| PT101732B (pt) | 1995-06-30 | 1997-12-31 | Portela & Ca Sa | Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso |
| AU7669496A (en) * | 1995-11-03 | 1997-05-22 | University Of Kentucky | Method for the intranasal administration of l-dopa prodrugs |
| IN190806B (es) | 1998-11-16 | 2003-08-23 | Max India Ltd | |
| DE19924148A1 (de) * | 1999-05-26 | 2000-12-07 | Univ Heidelberg | Sphingomyelinasehemmer |
| WO2002060936A2 (en) | 2001-01-31 | 2002-08-08 | University Of Iowa Research Foundation | Vaccine and compositions for the prevention and treatment of neisserial infections |
| US7261901B2 (en) * | 2001-01-31 | 2007-08-28 | University Of Iowa Research Foundation | Vaccine and compositions for the prevention and treatment of neisserial infections |
| IL157351A0 (en) | 2001-02-12 | 2004-02-19 | Teva Pharma | New crystal forms of oxcarbazepine and processes for their preparation |
| WO2006116157A2 (en) * | 2005-04-22 | 2006-11-02 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-iv inhibitors |
| WO2008139484A2 (en) | 2007-05-16 | 2008-11-20 | R. L. Fine Chem | New process for the synthesis of loferpramine maleate: a stable salt of loferpramine |
| KR101141938B1 (ko) * | 2010-01-22 | 2012-05-04 | 성균관대학교산학협력단 | 신규한 항생제 조성물 및 그람양성균의 치료 방법 |
| TWI619494B (zh) * | 2013-01-18 | 2018-04-01 | 華鴻新藥股份有限公司 | 巴豆酯之組成物及使用方法 |
| EP3250194A4 (en) | 2015-01-26 | 2018-08-08 | Institute for Clinical Pharmacodynamics, Inc. | Method for shortening anti-infective therapy duration in subjects with infection |
| US10201526B2 (en) | 2015-09-28 | 2019-02-12 | Research Institute At Nationwide Children's Hospital | Compositions and methods for inhibiting the growth of neisseria gonorrhoeae |
| CN105949075B (zh) | 2016-06-24 | 2017-11-07 | 江苏倍合德化工有限公司 | 一种甲芬那酸的合成方法 |
| CN108309983B (zh) * | 2018-01-15 | 2019-11-15 | 武汉百药联科科技有限公司 | 卡马西平在制备治疗黄病毒属病毒感染的药物中的应用 |
| US11013707B2 (en) * | 2018-03-23 | 2021-05-25 | The Regents Of The University Of Colorado, A Body Corporate | Administration of oral methyldopa |
| CN108324716A (zh) * | 2018-04-18 | 2018-07-27 | 日照市普达医药科技有限公司 | 一种含有茚地那韦的抗hiv药物及制备方法 |
-
2019
- 2019-09-30 WO PCT/AU2019/051055 patent/WO2020061649A1/en active Search and Examination
- 2019-09-30 US US17/280,603 patent/US20210338685A1/en active Pending
- 2019-09-30 EP EP19864039.3A patent/EP3856196B1/en active Active
- 2019-09-30 BR BR112021005955-5A patent/BR112021005955A2/pt unknown
- 2019-09-30 DK DK19864039.3T patent/DK3856196T3/da active
- 2019-09-30 KR KR1020217012936A patent/KR20210069086A/ko unknown
- 2019-09-30 AU AU2019348194A patent/AU2019348194A1/en active Pending
- 2019-09-30 CA CA3224977A patent/CA3224977A1/en active Pending
- 2019-09-30 MX MX2021003730A patent/MX2021003730A/es unknown
- 2019-09-30 EP EP23209820.2A patent/EP4295864A3/en active Pending
- 2019-09-30 CN CN201980078822.2A patent/CN113164494A/zh active Pending
- 2019-09-30 SG SG11202103183PA patent/SG11202103183PA/en unknown
- 2019-09-30 CA CA3115048A patent/CA3115048C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3856196B1 (en) | 2023-11-15 |
| US20210338685A1 (en) | 2021-11-04 |
| MX2021003730A (es) | 2021-06-18 |
| CA3224977A1 (en) | 2020-04-02 |
| CN113164494A (zh) | 2021-07-23 |
| DK3856196T3 (da) | 2024-02-19 |
| AU2019348194A1 (en) | 2021-04-29 |
| EP3856196A4 (en) | 2022-08-10 |
| WO2020061649A1 (en) | 2020-04-02 |
| KR20210069086A (ko) | 2021-06-10 |
| CA3115048C (en) | 2024-02-13 |
| EP4295864A2 (en) | 2023-12-27 |
| EP4295864A3 (en) | 2024-03-13 |
| EP3856196A1 (en) | 2021-08-04 |
| BR112021005955A2 (pt) | 2021-07-27 |
| CA3115048A1 (en) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271149A (en) | Compounds for modulating s1p1 activity and methods of using them | |
| IL269462B (en) | mdm2 inhibitors and therapeutic methods using them | |
| PL3718370T3 (pl) | Sposoby i powiązane urządzenia służące do realizacji funkcji multi-connectivity | |
| GB201820166D0 (en) | Therapeutic agents | |
| GB201820165D0 (en) | Therapeutic agents | |
| IL271025A (en) | Multibiotic substances and methods of using them | |
| GB201709456D0 (en) | Therapeutic agents | |
| IL285229A (en) | Compounds and methods for modulating RNA function | |
| EP3534910A4 (en) | THERAPEUTICS AND PROCEDURES | |
| IL273015A (en) | Beta-catenin functional modulators and methods thereof | |
| GB201805816D0 (en) | Therapeutic agents | |
| IL271728A (en) | Materials, uses and treatment methods | |
| SG11202100352YA (en) | Interaction method and device | |
| IL287079A (en) | Compositions and methods for regulating complement activity | |
| GB201820088D0 (en) | Opitical devices and methods | |
| IL286681A (en) | Compounds and methods for modulating ube3a-ats | |
| SG11202009940RA (en) | Device for creating track use plan, and method for creating track use plan | |
| EP3547934A4 (en) | NERVOUS REGENERATION DEVICES AND PROCESSES | |
| GB201700553D0 (en) | Therapeutic agents | |
| SG11202103183PA (en) | Agents and methods for modulating pathogen activity | |
| IL272732A (en) | activity modulator | |
| EP3331536A4 (en) | COMPOSITIONS AND METHODS FOR MODULATING ABHD2 ACTIVITY | |
| IL287709A (en) | par2 modulation and its methods | |
| GB201820170D0 (en) | Therapeutic agents | |
| GB201820160D0 (en) | Therapeutic agents |